Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Humoral Acute Rejection After Renal Transplantation
NCT01350882Phase 3Completed
- Sponsor
- University Hospital Tours
- Start
- Oct 2008
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in kidney transplant rejection comparing Rituximab with Placebo (2 arms). Primary endpoint: Treatment Failure at 1 year. Started Oct 2008; status: completed.
02
Drugs
rituximab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01350882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350882.